Venclose, Inc., a San Jose, CA-based medical technology company developing next-generation solutions for the treatment of venous reflux disease, closed a Series B round of financing.
New and existing investors participated in the round.
The company intends to use the proceeds for new product development, expansion of manufacturing capabilities and general corporate purposes.
Led by Jerry Gibson, Chairman and CEO, Venclose is commercializing the VENCLOSE™ Radiofrequency (RF) Ablation System, which is designed to close damaged veins and restore healthy blood flow in patients with venous reflux disease, a progressive medical condition which is often associated with varicose veins. To date, more than 4,000 patients in the United States and Europe have been treated with the VENCLOSE system.
Venclose also announced that Jeffrey G. Carr, MD, FACC, FSCAI has joined the company as Chief Medical Officer. In addition, Gregory J. Vislocky, who currently serves as Executive Vice President of Finance/Partner and Vice Chairman of the Board at Prestige Care, Inc., has been appointed to the Venclose Board of Directors.